<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03569241</url>
  </required_header>
  <id_info>
    <org_study_id>EC/2018/0130</org_study_id>
    <nct_id>NCT03569241</nct_id>
  </id_info>
  <brief_title>PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases</brief_title>
  <acronym>STORM</acronym>
  <official_title>PEACE V: A Randomized Phase II Trial for the Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A proportion of prostate cancer (PCa) patients develop relapse following curative local
      treatment. Regional nodal recurrence is an emerging clinical situation since the introduction
      of new molecular imaging methods in the restaging of recurrent prostate cancer. More
      specifically, a subgroup of these patients is being diagnosed with a recurrence confined to
      the regional lymph nodes and limited in number (oligorecurrence) using choline or PSMA
      PET-CT. As there are no specific treatment recommendations for these type of patients,
      different treatment approaches are currently used, mostly focusing on local ablative
      treatments using radiotherapy or surgery. These treatments are coined metastasisdirected
      therapy (MDT). MDT in combination with or without temporary ADT could delay the subsequent
      risk of progression, and even cure limited regional nodal recurrences. Consequently, lifelong
      palliative ADT, with its toxicity and excess in non-cancer mortality might be postponed.

      The proposed trial randomizes patients with oligorecurrent nodal prostate cancer following
      primary PCa treatment to either metastasis-directed therapy (MDT) (salvage lymph node
      dissection, sLND or stereotactic body radiotherapy, SBRT) or MDT plus whole pelvis
      radiotherapy (WPRT: 45 Gy in 25 fractions).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A proportion of prostate cancer (PCa) patients develop a local, regional (N1) or distant (M1)
      relapse following curative local treatment. For both local and distant relapses, different
      treatment recommendations are made in the guidelines (EAU guidelines 2016). However, the
      entity regional nodal recurrence is not mentioned in the guidelines but is an emerging
      clinical situation since the introduction of choline and more recently PSMA PET-CT in the
      restaging of recurrent prostate cancer. More specifically, a subgroup of these patients is
      being diagnosed with a recurrence confined to the regional lymph nodes and limited in number
      (oligorecurrence) using choline or PSMA PET-CT. As there are no specific treatment
      recommendations for these type of patients, different treatment approaches are currently
      used, mostly focusing on local ablative treatments using radiotherapy or surgery. These
      treatments are coined metastasisdirected therapy (MDT). MDT in combination with or without
      temporary ADT could delay the subsequent risk of metastases, and even cure limited regional
      nodal recurrences. Consequently, lifelong palliative ADT, with its toxicity and excess in
      non-cancer mortality might be postponed.

      The proposed trial randomizes patients with oligorecurrent nodal prostate cancer following
      primary PCa treatment to either metastasis-directed therapy (MDT) (sLND or SBRT) or MDT plus
      WPRT. In the recurrent PCa setting, 2 recent trials have suggested a progression-free and
      even survival benefit of adding temporary ADT to local salvage prostate bed radiotherapy.
      Consequently, this positive effect might also be applicable for regional recurrences.
      Although the optimal duration of ADT is unknown, a minimal duration of 6 months of ADT seems
      advisable in this setting and will be mandatory for both arms.

      This trial will improve our insights in the pattern of recurrence following these treatment
      modalities with the expectation that WPRT will reduce the number of nodal relapses, improving
      metastasis-free survival and postponing the need for palliative systemic treatments while
      maintaining quality-of-life. The current phase II trial will try to establish a golden
      standard in the treatment of oligorecurrent nodal PCa.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastases-free survival</measure>
    <time_frame>2 year</time_frame>
    <description>Metastasis-free survival will be defined as the time between randomization and the appearance of a metastatic recurrence (any M1) as suggested by choline, FACBC or PSMA PET-CT or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Progression free survival</measure>
    <time_frame>2 year</time_frame>
    <description>Clinical Progression-free survival is defined as time between randomization and the appearance of a new recurrence (any N1 or M1) as suggested by PET-CT, symptoms related to progressive PCa, or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical progression-free survival</measure>
    <time_frame>2 year</time_frame>
    <description>For patients who had previous RP at initial diagnosis, a biochemical recurrence is defined by any confirmed PSA rise above 0.20 ng/ml with a confirmatory rise at least 2 weeks later. For patients who had previous RT to the prostate at initial diagnosis, a biochemical recurrence is defined as the nadir + 2ng/ml (Phoenix definition). Non-responders are considered to have a biochemical recurrence in case a second measurement at least 2 weeks later confirms a rising PSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity: acute toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>Radiotherapy toxicity will be assessed according to NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity: late toxicity</measure>
    <time_frame>2 year</time_frame>
    <description>Radiotherapy toxicity will be assessed according to NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>2 year</time_frame>
    <description>QOL will be assessed by the summary score of the scale for bowel symptoms included in the EORTC QLQ.
Scale name: PRBOW. Higher values represent a worse outcome. Total range of total score: 0-100. The items (ranging from 1 to 4 on a Likert-scale) were converted into values ranging from 0 to 100. A score of 100 can be interpreted as maximal bowel symptoms.
PR-25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer-specific survival</measure>
    <time_frame>5 year</time_frame>
    <description>Cancer specific survival will be read as the time from trial randomization to the date of death due to prostate cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
    <description>Overall survival will be read as the time from trial randomization to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to start of hormonal treatment</measure>
    <time_frame>2 year</time_frame>
    <description>Time to hormonal treatment is defined as the time from trial randomization to start of hormonal treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to castration-resistant disease</measure>
    <time_frame>5 year</time_frame>
    <description>Time to castration resistant disease is defined as the time from trial randomization until castration resistant status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>economical evaluation</measure>
    <time_frame>2 year</time_frame>
    <description>Assessment of quality-adjusted-life-years with the EuroQol classification system (EQ-5D-5L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity/specificity of PET-CT for the detection of nodal recurrences: limited to patients undergoing surgery</measure>
    <time_frame>3 months</time_frame>
    <description>Sensitivity/specificity of PET-CT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Oligometastatic Cancer</condition>
  <arm_group>
    <arm_group_label>MDT + ADT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + 6 months androgen deprivation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDT + WPRT + ADT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + whole pelvic radiotherapy + 6 months androgen deprivation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>whole pelvic radiotherapy</intervention_name>
    <description>addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment</description>
    <arm_group_label>MDT + WPRT + ADT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>metastasis-directed treatment</intervention_name>
    <description>stereotactic body radiotherapy</description>
    <arm_group_label>MDT + ADT</arm_group_label>
    <arm_group_label>MDT + WPRT + ADT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>salvage Lymph Node Dissection</intervention_name>
    <description>metastasis-directed treatment</description>
    <arm_group_label>MDT + ADT</arm_group_label>
    <arm_group_label>MDT + WPRT + ADT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>androgen deprivation therapy</intervention_name>
    <description>LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months</description>
    <arm_group_label>MDT + ADT</arm_group_label>
    <arm_group_label>MDT + WPRT + ADT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven initial diagnosis of adenocarcinoma of the prostate

          -  Biochemical relapse of prostate cancer following radical local prostate treatment
             (radical prostatectomy, primary radiotherapy or radical prostatectomy +/- prostate bed
             adjuvant/ salvage radiotherapy) according to the EAU guidelines 2016.

          -  Following radical prostatectomy, patients with a biochemical relapse are eligible in
             case a nodal relapse is detected in the pelvis even in the absence of prior
             postoperative prostate bed radiotherapy (adjuvant or salvage).

          -  In case of a suspected local recurrence following primary radiotherapy, a biopsy
             should confirm local recurrence and patients with a confirmed local recurrence are
             eligible in case they also undergo a local salvage therapy. If imaging rules out local
             relapse, patients are eligible.

          -  Nodal relapse in the pelvis on choline, PSMA or FACBC PET-CT with a maximum of 3
             positive nodal lymph nodes. The upper limit of the pelvis is defined as the aortic
             bifurcation.

          -  WHO performance state 0-1

          -  Age &gt;18 years

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial

          -  Before patient registration/randomization, written informed consent must be given
             according to ICH/GCP, and national/local regulations.

        Exclusion Criteria:

          -  Bone or visceral metastases

          -  Para-aortic lymph node metastases (above the aortic bifurcation)

          -  Local relapse in the prostate gland or prostate bed not suitable for a curative
             treatment

          -  Previous irradiation of the pelvic and or para-aortic nodes

          -  Serum testosterone level &lt;50ng/dl or 1.7 nmol/L at time of randomization

          -  Symptomatic metastases

          -  Lymph node metastases in previously irradiated areas resulting in dose constraint
             violation

          -  Contraindications to pelvic radiotherapy (chronic pelvic inflammatory bowel disease)

          -  Contraindications to androgen deprivation therapy

          -  PSA rise while on active treatment with (LHRH-agonist, LHRH-antagonist, anti-androgen,
             estrogen

          -  Previous treatment with cytotoxic agent for PCa

          -  Treatment during the past month with products known to influence PSA levels (e.g.
             fluconazole, finasteride, corticosteroids,…)

          -  Other active malignancy, except non-melanoma skin cancer or other malignancies with a
             documented disease-free survival for a minimum of 3 years before randomization.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piet Ost, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piet Ost, PhD</last_name>
    <phone>003293323045</phone>
    <email>piet.ost@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Epworth Healthcare</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shankar Siva, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Nathan Lawrentschuk, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GZA</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piet Dirix, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ St-Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine Meersschout, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ St-Lucas</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lien Van De Voorde, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Xavier Otte, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Ameye, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piet Ost, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Piet Ost, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Liefhooghe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wouter Everaerts, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Mouscron</name>
      <address>
        <city>Mouscron</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Junius, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Axel Merseburger, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Jereczek, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Scorsetti, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Ciro Franzese, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vita-Salute San Raffaele University</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Briganti, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Filippi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore-Don Calabria</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Filippo Alongi, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Niccolo Giaj Levra, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shafak Al-Uwini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reino Heikkilä, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cruces University Hospital</name>
      <address>
        <city>Barakaldo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Gomez-Iturriaga, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando Lopez Campos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Almudena Zapatero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitario Quironsalud</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Couñago, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Santiago</name>
      <address>
        <city>Santiago</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paula Higuero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio José Conde-Moreno, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandros Papachristofilou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Radio-Onkologie</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Shelan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Zilli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Martin Putora, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Guckenberger, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>metastasis-directed therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

